US Patent Issued to Chia Tai Tianqing Pharmaceutical Group, Medshine Discovery on Sept. 23 for "Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor" (Chinese Inventors)

ALEXANDRIA, Va., Sept. 23 -- United States Patent no. 12,421,236, issued on Sept. 23, was assigned to Chia Tai Tianqing Pharmaceutical Group Co. Ltd. (Lianyungang, China) and Medshine Discovery Inc. (Nanjing, China).

"Seven-membered heterocyclic derivative acting as KRAS G12C mutant protein inhibitor" was invented by Charles Z. Ding (Shanghai) and Shuhui Chen (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "A class of KRAS G12C mutant protein inhibitors, specifically disclosing the compound shown in formula (I), and an isomer and a pharmaceutically acceptable salt thereof."

The patent was filed on June 24, 2020, under Application No. 17/621,621.

*For further information, including images, charts an...